ProShare Advisors’s Mirum Pharmaceuticals MIRM Stock Holding History

ProShare Advisors’s Portfolio MIRM Stock Details MIRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$814K	Sell	8,813 -961	-10%	-$90.4K	﹤0.01%	851
2025 Q4	$772K	Buy	9,774 +1,082	+12%	+$77.7K	﹤0.01%	914
2025 Q3	$637K	Sell	8,692 -2,073	-19%	-$132K	﹤0.01%	982
2025 Q2	$548K	Sell	10,765 -45	-0.4%	-$2K	﹤0.01%	1074
2025 Q1	$487K	Sell	10,810 -2,647	-20%	-$125K	﹤0.01%	1116
2024 Q4	$556K	Buy	13,457 +3,227	+32%	+$134K	﹤0.01%	1212
2024 Q3	$399K	Buy	10,230 +4,006	+64%	+$160K	﹤0.01%	1276
2024 Q2	$213K	Buy	+6,224	New	+$163K	﹤0.01%	1500
2024 Q1	–	Sell	-7,074	Closed	-$209K	–	2016
2023 Q4	$209K	Buy	+7,074	New	+$214K	﹤0.01%	1613

Other funds holding MIRM

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

ProShare Advisors's MIRM Position: Q1 2026 in Review

ProShare Advisors reduced its Mirum Pharmaceuticals (MIRM) stake by 9.8% in Q1 2026, selling an estimated $90.4K and leaving 8,813 shares worth $814K. The position accounts for ﹤0.01% of the portfolio, ranked #851.

ProShare Advisors first reported a position in MIRM in Q4 2023 and has held it in 9 quarters since. 311 funds tracked by Wall St. Rank hold MIRM as of Q1 2026.

ProShare Advisors held 8,813 shares of Mirum Pharmaceuticals worth $814K as of Q1 2026.
ProShare Advisors sold 961 Mirum Pharmaceuticals shares in Q1 2026, an estimated $90.4K.
Mirum Pharmaceuticals made up ﹤0.01% of ProShare Advisors's portfolio in Q1 2026, its #851 holding.
ProShare Advisors first reported a position in Mirum Pharmaceuticals in Q4 2023 and has held it in 9 quarters since.
311 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.